# Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC

> **NCT06725498** · PHASE2 · RECRUITING · sponsor: **Beijing Tongren Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Tislelizumab-jsgr
- **DRUG:** Cisplatin
- **DRUG:** Albumin-Bound Paclitaxel
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT06725498
- **Lead sponsor:** Beijing Tongren Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-01
- **Primary completion:** 2026-11-30
- **Final completion:** 2029-11-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06725498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06725498, "Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT06725498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*